Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmasset, a clinical-stage pharmaceutical company, has initiated dosing in a Phase I, single ascending dose study in healthy volunteers with PSI-7851, a second generation nucleotide analog polymerase inhibitor of hepatitis C virus.
Subscribe to our email newsletter
Pharmasset has filed an investigational new drug application with the FDA earlier in this quarter of 2009.
Michelle Berrey, chief medical officer of Pharmasset, said: “This is a significant milestone for Pharmasset. PSI-7851 is a wholly owned, second generation nucleotide analog that was discovered by Pharmasset scientists.
“We continue to see nucleos(t)ide inhibitors as having the potential to be the cornerstone of future hepatitis C virus (HCV) treatment, given their higher barrier to resistance and antiviral activity across multiple HCV genotypes, characteristics that set them apart from other HCV drug classes. We look forward to reporting the first antiviral data with PSI-7851 in the second half of 2009.”